Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Research & Development (2016 - 2025)

Avalo Therapeutics' Research & Development history spans 12 years, with the latest figure at $13.3 million for Q4 2025.

  • For Q4 2025, Research & Development rose 62.13% year-over-year to $13.3 million; the TTM value through Dec 2025 reached $50.1 million, up 104.95%, while the annual FY2025 figure was $50.1 million, 104.95% up from the prior year.
  • Research & Development reached $13.3 million in Q4 2025 per AVTX's latest filing, down from $13.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $25.2 million in Q1 2021 to a low of $1.2 million in Q3 2023.
  • Average Research & Development over 5 years is $9.0 million, with a median of $8.8 million recorded in 2022.
  • Peak YoY movement for Research & Development: tumbled 82.26% in 2023, then skyrocketed 663.65% in 2024.
  • A 5-year view of Research & Development shows it stood at $11.5 million in 2021, then plummeted by 46.38% to $6.2 million in 2022, then tumbled by 69.75% to $1.9 million in 2023, then soared by 338.3% to $8.2 million in 2024, then skyrocketed by 62.13% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Research & Development are $13.3 million (Q4 2025), $13.6 million (Q3 2025), and $14.1 million (Q2 2025).